Posted by Michael Wonder on 18 Sep 2025
Vorasidenib approved to treat patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation
16 September 2025 - The MHRA has today approved the medicine vorasidenib (Voranigo).
Vorasidenib has been approved through Project Orbis, a global partnership between the MHRA, and its regulatory counterparts in Australia, Canada, Singapore, Switzerland, Brazil, and Israel, coordinated by the US FDA.
